Know Cancer

or
forgot password

Phase 2 Study of Chemoradiotherapy for Advanced Gastric Cancer


Phase 2
18 Years
75 Years
Not Enrolling
Both
Gastric Cancer

Thank you

Trial Information

Phase 2 Study of Chemoradiotherapy for Advanced Gastric Cancer


Inclusion Criteria:



1. Postoperative histologically confirmed advanced adenocarcinoma of the stomach or the
gastroesophageal junction.

2. Age of 18 to 75, Karnofsky score higher than 70.

3. Postoperative histologically conformed metastasis in perigastric lymph nodes and/or
tumor invasion to muscularis propria or subserosa, with or without positive incisal
margin.

4. No severe functional damage of major organ, normal blood cell, normal liver and
kidney function.

5. No clinical findings of distant metastasis.

6. Predictive survival time longer than 6 months.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall survival

Outcome Time Frame:

1 year

Safety Issue:

Yes

Principal Investigator

Shiying Yu, Master

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tongji Cancer Center

Authority:

China: Ethics Committee

Study ID:

TJCC-GC001

NCT ID:

NCT01197118

Start Date:

September 2010

Completion Date:

May 2011

Related Keywords:

  • Gastric Cancer
  • gastric cancer
  • sequence chemoradiotherapy
  • OLF regimen
  • survival rate
  • Stomach Neoplasms

Name

Location